Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) CFO Catherine Isted joined Proactive's Stephen Gunnion to discuss a standout 2025, with total revenues almost doubling to CHF 77.2 million — well ahead of guidance — driven by strong AGAMREE sales across Europe and partner contributions from the US and China. European approvals now cover around 80% of major markets, with Spain and Italy the next launches. Long-term data continues to support AGAMREE's differentiated safety profile versus traditional corticosteroids, while a new Asia-Pacific licensing deal and further partnership opportunities are being explored. Operating expenses fell to CHF 53 million, and the company expects to reach cash flow breakeven in Q3 2026 — without needing to raise additional capital. For more insights into Santhera Pharmaceuticals’ strategy and growth outlook, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #SantheraPharmaceuticals #AGAMREE #DMD #Biotech #PharmaNews #HealthcareInnovation #DrugDevelopment #RareDisease #Investing #BiotechStocks #EuropeMarkets